B2M Knockout HEK293T Cell Line

The choice depends on whether you are studying B2M (β-2-microglobulin)'s role as the essential MHC class I light chain or modeling its applications in checkpoint inhibitor resistance and universal allogeneic CAR-T platforms. The Knockout line is the standard tool for asking whether B2M is required for these processes — B2M is the non-polymorphic light chain of all MHC class I molecules (HLA-A, HLA-B, HLA-C); B2M is required for MHC class I surface expression — B2M loss eliminates virtually all MHC I surface presentation, enabling immune evasion in cancer and serving as a strategy for universal allogeneic cell therapy platforms. Overexpression is useful for studying B2M gain-of-function effects. For cancer immunology research, the EDITGENE B2M Knockout in HEK293T is uniquely valuable — HEK293T's very high transfection efficiency supports systematic structure-function studies. This product complements the parallel B2M Knockouts in A-549 and A-375 (both also available) for cancer context-specific studies. Rescue with wild-type B2M is the standard specificity control. The knockout is a critical specificity tool for ⭐⭐⭐ checkpoint inhibitor resistance research (B2M loss-of-function mutations are a major mechanism of acquired resistance to pembrolizumab/nivolumab/ipilimumab); ⭐⭐ universal CAR-T cell development (B2M KO eliminates HLA-class I to enable allogeneic 'off-the-shelf' CAR-T cells, used in CTX110/CTX120/CTX130 platforms); and emerging cancer immune evasion mechanism studies.

Primary applications: • MHC class I surface expression: anti-HLA-ABC flow cytometry analysis — B2M KO eliminates virtually all surface MHC I. • Universal CAR-T platform: critical genetic background for ⭐⭐ allogeneic 'off-the-shelf' CAR-T cells (CTX110 anti-CD19, CTX120 anti-BCMA, CTX130 anti-CD70) — B2M KO prevents host-versus-graft rejection. • HLA-knockout iPSC platforms: critical for stem cell-derived universal cell therapy products. • Cross-background validation: parallel analysis with B2M KOs in A-549 (lung) and A-375 (melanoma) for tissue-specific studies. EDITGENE recommends this HEK293T-based model for systematic B2M biochemistry and universal allogeneic CAR-T platform development.

Yes. B2M rescue experiments are well-established for MHC I research: • Construct design: use a codon-modified B2M sequence with a small C-terminal tag (FLAG, HA, after the signal peptide). B2M is a small soluble light chain (~12 kDa) — preserve all elements. • MHC class I surface restoration: rescue with WT B2M should restore HLA-ABC surface expression measured by flow cytometry (anti-pan-HLA-I clone W6/32). • Universal CAR-T validation: WT B2M rescue restores allorecognition by host T cells — useful for verifying B2M-dependent HvG. • Functional readout: rescue should restore CD8+ T cell-mediated cytotoxicity in MHC I-restricted contexts. HEK293T transduces with very high efficiency and supports stable rescue line generation.